View Cart (0 items)

Pharmaceutical

Merck to take over hepatitis C drug maker

American pharmaceutical giant Merck & Co. is planning to buy Idenix Pharmaceuticals Inc., a Massachusetts-based company specializing in developing treatment for hepatitis C.
Read More

Teva gets approval for generic version of pain reliever Celebrex

The U.S. Food and Drug Administration (FDA) has approved the first generic versions of pain relieving drug product Celebrex (celecoxib).
Read More

Hikma Pharmaceuticals to take over US generic injectables manufacturer

London-based multinational company Hikma Pharmaceuticals PLC has reached an asset acquisition agreement with Ben Venue Laboratories for the purchase of its U.S. generic injectables division, Bedford Laboratories, for $300 million.
Read More

US pharma major Abbott to pay $2.9 billion for Chile's CFR

U.S. pharmaceuticals and healthcare products major Abbott Laboratories has agreed to acquire Chile-based pharmaceutical firm CFR Pharmaceuticals SA in a deal worth $2.9 billion.
Read More

Sun Pharma's response to FDA import ban seen as 'inadequate'

According to the U.S. Food and Drug Administration, Sun Pharma has failed to take sufficient measures to correct the violations that led to the enforcement action.
Read More

Teva recalls 39,000 bottles of drug products due to manufacturing standards violations

The recalled production includes 2,532 bottles of anti-diabetes drug glyburide, which are being pulled off the U.S. market due to deviations from Current Good Manufacturing Practice.
Read More

EU, US health officials team up to fight antimicrobial resistance

Health officials from both sides of the Atlantic have been working together to tackle antimicrobial resistance under their joint Transatlantic Taskforce on Antimicrobial Resistance.
Read More

Bayer to take over Merck's consumer care business in $14.2 billion deal

German pharmaceutical giant Bayer is acquiring the over-the-counter medicines business of U.S. rival Merck & Co., Inc.
Read More

Sanofi looking to shed multi-billion portfolio to optimize assets

French pharmaceutical giant Sanofi SA is exploring options to sell a range of older drugs, with an estimated value of the portfolio between $7 billion and $8 billion.
Read More

US wholesale sector consolidation hits Indian drug makers

The U.S. pharmaceutical sector is going through a period of consolidation and this has already has a noticeable effect on Indian drug makers.
Read More